Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Astellas Pharma Inc.    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Astellas Pharma : AMGEN ASTELLAS BIOPHARMA TO BECOME A WHOLLY OWNED AMGEN AFFILIATE ON APRIL 1, 2020 THE NEW COMPANY NAME WILL BE AMGEN K.K. THE HEADQUARTERS WILL RELOCATE TO TOKYO MIDTOWN

01/23/2020 | 01:39am EST

Co-Promotion of Repatha®, EVENITY®, and BLINCYTO® to Continue with Astellas

Amgen Inc. (Headquarters: Thousand Oaks, California, USA; Chairman and CEO: Robert A. Bradway; 'Amgen'), Astellas Pharma Inc. (Headquarters: Tokyo; President and CEO: Kenji Yasukawa, PhD., 'Astellas'), and Amgen Astellas BioPharma K.K. (Headquarters: Tokyo; President and Representative Director: Steve Sugino; 'Amgen Astellas BioPharma') announced that on April 1, 2020, Amgen will purchase the 49% of shares in Amgen Astellas BioPharma that are held by Astellas, based on the strategic alliance contract signed between Amgen and Astellas in 2013, making the company a wholly owned Amgen affiliate.

With this, Amgen Astellas BioPharma will change its name to Amgen K.K., and simultaneously relocate its Headquarters to Tokyo Midtown (9-7-1 Akasaka, Minato-ku, Tokyo). Steve Sugino will continue to serve as President and Representative Director of Amgen K.K.

Amgen Astellas BioPharma commenced business in October 2013, bringing together the strengths of Amgen, one of the world's leading independent biotechnology companies, and Astellas, a company with deep knowledge of the medical needs in Japan and a wealth of experience in the development and marketing of pharmaceutical products, as well as a strong business foundation, to contribute to healthcare in Japan through the provision of innovative medicines created by Amgen.

Since then, Amgen Astellas BioPharma and Astellas have worked together to serve patients in Japan with cardiovascular disease, cancer, and bone disease, which are three areas of significant unmet medical needs, launching Repatha® for familial hypercholesterolemia (FH) or hypercholesterolemia for patients who have high cardiovascular event risk and do not adequately respond to HMG-CoA reductase inhibitors, BLINCYTO® for patients with relapsed or refractory B-cell acute lymphoblastic leukemia, and EVENITY® for osteoporosis patients at high risk of fracture. Amgen K.K. and Astellas will continue to co-promote these three products and Astellas will remain responsible for distribution and sales of the products beyond 2020.

Amgen K.K. will carry forward Amgen's global mission to serve patients by delivering breakthrough-science-based medicines, while also striving to bring Amgen's full global pipeline of innovative medicines to patients in Japan who face unmet medical needs.

Click below for a copy of the full press release

Disclaimer

Astellas Pharma Inc. published this content on 23 January 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 23 January 2020 06:33:02 UTC


© Publicnow 2020
All news about ASTELLAS PHARMA INC.
11/30Astellas Receives Approval of EVRENZO in Japan for the Treatment of Anemia of..
AQ
11/26ASTELLAS PHARMA : Launches a 'Contact for Potential Acquisition of ' R&D Program..
AQ
11/19Japan shares fall as virus surge, firmer yen weigh
RE
11/17ASTELLAS PHARMA : to Present New Data on Gilteritinib in FLT3 Mutation-Positive ..
AQ
11/09ASTELLAS PHARMA INC. : - XTANDI Approved by China NMPA for the Treatment of Non-..
AQ
11/02ASTELLAS PHARMA : Completes Acquisition of iota Biosciences
AQ
10/30Japan stocks fall, post biggest weekly loss in 3 months on virus worries
RE
10/30Japanese shares slump on virus worries, mixed earnings
RE
10/28ASTELLAS PHARMA : Receives U.S. FDA Fast Track Designation for ASP5354, an Inves..
AQ
10/27ASTELLAS PHARMA INC. : half-yearly earnings release
More news
Financials
Sales 2021 1 272 B 12 177 M 12 177 M
Net income 2021 190 B 1 816 M 1 816 M
Net cash 2021 444 B 4 252 M 4 252 M
P/E ratio 2021 14,7x
Yield 2021 2,80%
Capitalization 2 790 B 26 686 M 26 716 M
EV / Sales 2021 1,84x
EV / Sales 2022 1,67x
Nbr of Employees 15 883
Free-Float 99,2%
Chart ASTELLAS PHARMA INC.
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | 4503 | JP3942400007 | MarketScreener
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 2 275,00 JPY
Last Close Price 1 502,00 JPY
Spread / Highest target 113%
Spread / Average Target 51,5%
Spread / Lowest Target 9,85%
EPS Revisions
Managers
NameTitle
Kenji Yasukawa President, CEO & Representative Director
Yoshihiko Hatanaka Chairman
Naoki Okamura Representative Director & Vice President
Tomokazu Fujisawa Director
Hiroko Sakai Director
Sector and Competitors
1st jan.Capitalization (M$)
ASTELLAS PHARMA INC.-19.68%26 723
JOHNSON & JOHNSON1.08%388 168
ROCHE HOLDING AG-4.59%284 650
PFIZER, INC.6.17%219 056
MERCK & CO., INC.-10.34%206 324
NOVARTIS AG-11.46%205 415